Herbalife (NYSE:HLF) Beats Q2 CY2026 Sales Expectations
Herbalife (NYSE:HLF) reported Q2 CY2026 revenue of $1.33 billion, up 5.4% year on year and about 1.5% above Wall Street estimates, according to the company. It guided next-quarter revenue near $1.31 billion. Non-GAAP EPS was $0.51, missing consensus by 4.9%. Shares fell 3.4% to $12.16 after results.
How this was made
The 30-second read
Why it matters
Traders can reassess near-term expectations using the provided Q2 revenue beat, EPS miss, and next-quarter revenue guidance around $1.31B, while weighing weaker non-GAAP profit and EBITDA guidance.
Market read
A revenue beat with near-consensus revenue guidance, but EPS and EBITDA guidance misses, aligns with the reported 3.4% post-report stock decline.
What to watch
Free cash flow was positive but low ($21.6M, 1.6% margin) and regressed YoY, which may cap valuation support even if revenue trends improve.
Background
The article frames Herbalife’s Q2 CY2026 results versus Wall Street expectations and discusses cash profitability and longer-term sales growth.
Ticker impact
Herbalife reported Q2 CY2026 revenue of $1.33B, up 5.4% YoY, beating expectations by 1.5%, and guided next-quarter revenue near $1.31B.
Choppy trading risk: initial post-report drop of 3.4% suggests the market discounted the EPS miss despite the revenue beat.
The article provides both the beat (revenue) and the misses (EPS vs consensus, EBITDA guidance shortfall) plus same-day price reaction, which together point to mixed fundamentals rather than a clean re-rating.
Market effects
Consumer staples and health-and-wellness peers may see read-across on demand durability and cash profitability, but this is company-specific.
Primarily US-listed single-name impact; no regional macro linkage stated.
No explicit global supply, regulatory, or macro drivers mentioned.
Counterpoint
The revenue beat and modest next-quarter guide near estimates could still support a rebound if investors focus on top-line stabilization rather than EPS/EBITDA misses.
Key entities
- companyHerbalife
Health and wellness products company reporting Q2 CY2026 results and next-quarter revenue guidance.
- market_referenceWall Street estimates
Consensus revenue and EPS benchmarks used to judge the beat/miss.
